Skip to Main Content

A Phase II, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma

Conditions

Melanoma, skin

Phase II

What is the purpose of this trial?

Prospective, single-arm interventional study evaluating autologous tumor infiltrating lymphocyte (TIL) infusion (LN-144) followed by IL-2 after a non-myeloablative chemotherapy preparative regimen for the treatment of metastatic melanoma.

  • Trial with
    Lion Biotechnologies, Inc.
  • Start Date
    01/19/2016
  • End Date
    03/30/2020
Trial Image

For more information about this study, contact:

Neta Shanwetter Levit

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/28/2019
  • Study HIC
    #1506016045